Finnhub•2026-04-20
Sutro Biopharma Presents Promising Preclinical Data Across Its Pipeline of Next-Generation Single and Dual-Payload Adc ProgramsSTRO — Sutro Biopharma Inc
NASDAQ · Biotechnology · Biotechnology
$34.35+249.44%Market cap389.25M
- Latest Close
- $34.35
- 30-Day Move
- +249.4%
- Market Cap
- $389M
- Shares Outstanding
- 16,430,000
- P/B Ratio
- 3.4
- ROE
- -510.0%
NASDAQ:STROBiotechnology / BiotechnologyDelayed public snapshot
Sutro Biopharma Inc
A read-only Alphactor snapshot forSutro Biopharma Inc. It uses the same research structure as the app, but with delayed data and shallow depth so search visitors can evaluate the stock before signing up.
Snapshot as of2026-04-21
Topline snapshot
Latest Close
$34.35
30-Day Move
+249.4%
Market Cap
$389M
Shares Outstanding
16,430,000
P/B Ratio
3.4
ROE
-510.0%
Not investment advice. Signals and scores shown here are model outputs derived from historical data, not recommendations. Past performance does not guarantee future results. Do your own research before trading. Full disclaimer
Chart snapshot
$34.35
+249.4%last 90 delayed daily bars
Market cap$389M
90D High
$35.40
90D Low
$8.48
Avg Volume
162,148
What stands out
Net margin is -186.4%, useful for comparing STRO against peers in Biotechnology.
STRO is up 249.4% over the last 30 trading days shown on this page.
Latest operating income is $-105M, which helps anchor the headline ratios with an actual earnings figure.
Research snapshot
Composite Fair Value
$33.77
Rule of 40
-109.4%
Dark Pool Short %
68.0%
Fundamentals snapshot
Latest Close
$34.35
30-Day Move
+249.4%
Market Cap
$389M
Shares Outstanding
16,430,000
P/B Ratio
3.4
ROE
-510.0%
ROA
-109.9%
Operating Margin
-154.5%
Net Margin
-186.4%
Debt / Equity
0
Current Ratio
2.01
Latest Revenue
$102M
Financial statement snapshot
Revenue
$102M
Gross Profit
--
Operating Income
$-105M
Net Income
$-191M
Gross Margin
--
Net Margin
-18645.0%
Current Ratio
2.01
Debt / Equity
0.00
Valuation snapshot
Fair Value
$33.77
Upside / Downside
-1.7%
Signal
Fairly Valued
Implied Growth
--
EV/Rev
$33.77
Growth Assumption
14.8%
Discount Rate
10.5%
Terminal Growth
2.0%
Base FCF
--
Valuation spread
Current Price
$34.35
Composite Fair Value
$33.77
EV/Rev
$33.77
After signup
The full valuation workspace goes deeper
Adjust DCF growth, discount, and terminal assumptions instead of relying on one static snapshot.
Open the deeper balance-sheet and cash-flow views to inspect debt, liquidity, and cash generation line by line.
Compare multiple valuation models against peers and save your own thesis instead of re-reading a fixed public state.
Negative FCF — company is cash-flow negative. Reverse DCF requires positive cash flows.
Quality snapshot
Altman Z
-7.99
Distress
Piotroski
2
Weak (0-3)
Cash Conversion
0.93x
Rule of 40
-109.4%
Concerning
Annual financial history
Annual performance mix
| Period | Revenue | Operating Income | Net Income | Free Cash Flow |
|---|---|---|---|---|
| 2022-12-31 | $68M | $-129M | $-119M | $-4M |
| 2023-12-31 | $154M | $-89M | $-107M | $-116M |
| 2024-12-31 | $62M | $-238M | $-227M | $-195M |
| 2025-12-31 | $102M | $-105M | $-191M | $-179M |
After signup
The app opens the full statement deep dive
Extend the history well beyond this public snapshot to inspect longer cycles and regime changes.
Move from summary lines into detailed balance-sheet and cash-flow rows for working capital, debt, and capex analysis.
Cross-link statement changes with alerts, watchlists, and saved research workflows after signup.
News snapshot
Benzinga•2026-04-20
Reported Sunday, Sutro Biopharma's STRO-004 Demonstrates Robust Antitumor Activity Across TF-Expressing Solid Tumor PDX Models With Improved Efficacy Versus Benchmark ADCs At AACR 2026Finnhub•2026-04-19
Sutro Biopharma Presents Promising Preclinical Data Across its Pipeline of Next-Generation Single and Dual-Payload ADC Programs at AACR 2026Benzinga•2026-04-17
Citizens Maintains Market Outperform on Sutro Biopharma, Raises Price Target to $35After signup
The full sentiment workspace adds context
Go past the public headlines into fuller article history, source cross-checks, and deeper narrative tracking.
Tie news into alerts, watchlists, and conviction changes instead of browsing one static batch of stories.
ETF holders snapshot
| ETF | Shares | Weight | As Of |
|---|---|---|---|
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 235,624 | 0.01% | 2025-12-31 |
| VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund | 81,540 | 0.00% | 2025-12-31 |
| Fidelity Concord Street Trust-Fidelity Extended Market Index Fund | 43,751 | 0.00% | 2026-02-28 |
| iShares Trust-iShares Micro-Cap ETF | 20,894 | 0.00% | 2026-02-28 |
| Invesco Exchange-Traded Fund Trust-Invesco RAFI US 1500 Small-Mid ETF | 17,015 | 0.00% | 2026-02-28 |
| Fidelity Concord Street Trust-Fidelity Total Market Index Fund | 13,417 | 0.00% | 2026-02-28 |
| Fidelity Concord Street Trust-Fidelity Series Total Market Index Fund | 11,118 | 0.00% | 2026-02-28 |
| VANGUARD VALLEY FORGE FUNDS-Vanguard Balanced Index Fund | 4,908 | 0.00% | 2025-12-31 |
After signup
The deeper ownership view shows who is leaning in
Open richer institutional and holder diffs to see position changes across filings instead of one static snapshot.
Use those ownership shifts alongside conviction and alerts in the full app workflow.
Institutional holders snapshot
Vanguard Group
Filed 2026-01-29
--
--
Northern Trust
Filed 2026-02-17
--
--
Charles Schwab
Filed 2025-08-12
--
--
Qube Research & Technologies
Filed 2026-02-17
--
--
Invesco
Filed 2026-02-19
--
--
FMR LLC (Fidelity)
Filed 2026-02-17
--
--
Goldman Sachs
Filed 2026-02-10
--
--
Geode Capital Management
Filed 2026-02-09
--
--
Dark-pool activity snapshot
For informational and educational purposes only. Not financial advice. Learn more
Related reading
Research and strategy guides from the alphactor blog.
Accruals Quality: How to Spot Earnings That Aren't Real
Accruals measure the gap between reported earnings and actual cash. Widening accruals is one of the most reliable red flags in financial analysis — Sloan's…
Altman Z-Score: A Bankruptcy Predictor That Still Works
Edward Altman's 1968 discriminant model predicts bankruptcy within two years about 72% of the time at its distress threshold.
Balance Sheet Deep Dive
Balance sheet changes lead income statements by 2-6 quarters. Net debt, receivables days, and goodwill are the lines that move stocks first.